|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
ES2776698T3
(es)
|
2012-12-20 |
2020-07-31 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
SI3456831T1
(sl)
|
2013-04-16 |
2021-11-30 |
Regeneron Pharmaceuticals, Inc., |
Ciljna modifikacija podganjega genoma
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
EP3988649B1
(en)
|
2013-09-18 |
2024-11-27 |
Kymab Limited |
Methods, cells and organisms
|
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
|
KR102523466B1
(ko)
|
2013-11-07 |
2023-04-20 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
|
WO2015073644A1
(en)
*
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
US9546384B2
(en)
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
|
JP2017503485A
(ja)
*
|
2013-12-12 |
2017-02-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
遺伝子産物の発現、構造情報、及び誘導性モジュラーｃａｓ酵素を変更するためのｃｒｉｓｐｒ−ｃａｓ系並びに方法
|
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
|
EP3082853A2
(en)
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
CA3161903C
(en)
|
2014-02-11 |
2025-09-09 |
Univ Colorado Regents |
Crispr enabled multiplexed genome engineering
|
|
CA2937711C
(en)
|
2014-02-14 |
2020-10-20 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
US11439712B2
(en)
|
2014-04-08 |
2022-09-13 |
North Carolina State University |
Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
|
|
EP3129473B8
(en)
*
|
2014-04-11 |
2020-12-23 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
|
US20170029805A1
(en)
*
|
2014-04-14 |
2017-02-02 |
Maxcyte, Inc. |
Methods and compositions for modifying genomic dna
|
|
EP3800248A3
(en)
*
|
2014-04-18 |
2021-08-04 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
WO2016033298A1
(en)
|
2014-08-28 |
2016-03-03 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
|
AU2015339744B2
(en)
|
2014-10-31 |
2021-03-25 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in CART cells and uses thereof
|
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
GB201421096D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
RU2020120613A
(ru)
|
2014-12-05 |
2021-12-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
|
|
WO2016090320A1
(en)
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
BR112017011914A2
(pt)
|
2014-12-05 |
2018-02-27 |
Memorial Sloan-Kettering Cancer Center |
?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
|
|
KR102612367B1
(ko)
|
2014-12-05 |
2023-12-12 |
메모리얼 슬로안 케터링 캔서 센터 |
G-단백질 커플화 수용체를 표적화하는 키메라 항원 수용체 및 그의 용도
|
|
CN109072199B
(zh)
|
2014-12-05 |
2022-10-28 |
纪念斯隆-凯特琳癌症中心 |
靶向Fc受体样5的嵌合抗原受体及其用途
|
|
AU2015367317A1
(en)
*
|
2014-12-17 |
2017-06-01 |
Cellectis |
Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
|
WO2016098078A2
(en)
*
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
RU2017129455A
(ru)
|
2015-01-26 |
2019-03-04 |
Селлектис |
Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток
|
|
AU2016211161C1
(en)
*
|
2015-01-30 |
2023-11-23 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
AU2016214301B2
(en)
*
|
2015-02-06 |
2022-05-19 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
|
JP6895380B2
(ja)
|
2015-02-06 |
2021-06-30 |
ナショナル ユニバーシティ オブ シンガポール |
治療免疫細胞の有効性を改良するための方法
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016137949A1
(en)
*
|
2015-02-23 |
2016-09-01 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3268388A1
(en)
|
2015-03-11 |
2018-01-17 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
CN107847524A
(zh)
*
|
2015-03-27 |
2018-03-27 |
哈佛学院校长同事会 |
经过修饰的t细胞及其制备和使用方法
|
|
EP4600366A3
(en)
*
|
2015-03-31 |
2025-10-22 |
SOHM, Inc. |
Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
|
|
JP6873911B2
(ja)
|
2015-04-06 |
2021-05-19 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
|
|
WO2016167300A1
(ja)
|
2015-04-13 |
2016-10-20 |
国立大学法人東京大学 |
光依存的に又は薬物存在下でヌクレアーゼ活性若しくはニッカーゼ活性を示す、又は標的遺伝子の発現を抑制若しくは活性化するポリペプチドのセット
|
|
ES3039918T3
(en)
|
2015-04-13 |
2025-10-27 |
Pfizer |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
US11608511B2
(en)
|
2015-04-13 |
2023-03-21 |
Maxcyte, Inc. |
Methods for modifying genomic DNA
|
|
JP2018515139A
(ja)
|
2015-05-08 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
万能ドナー幹細胞および関連する方法
|
|
KR20180029201A
(ko)
|
2015-05-18 |
2018-03-20 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
|
|
US10576076B2
(en)
|
2015-05-20 |
2020-03-03 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
|
IL302102A
(en)
|
2015-05-20 |
2023-06-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
AU2016271147B2
(en)
*
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
CN108026536A
(zh)
|
2015-05-29 |
2018-05-11 |
北卡罗来纳州立大学 |
使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
|
|
ES2960226T3
(es)
|
2015-06-15 |
2024-03-01 |
Univ North Carolina State |
Métodos y composiciones para la administración eficiente de ácidos nucleicos y antimicrobianos basados en ARN
|
|
US11555207B2
(en)
|
2015-06-17 |
2023-01-17 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
JP2018518182A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
EP3310395A4
(en)
*
|
2015-06-18 |
2019-05-22 |
Robert D. Bowles |
REGULATION OF RNA GUIDED TRANSCRIPTION AND METHODS OF USE THEREOF FOR THE TREATMENT OF LOMBALGIA
|
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
US20170020922A1
(en)
*
|
2015-07-16 |
2017-01-26 |
Batu Biologics Inc. |
Gene editing for immunological destruction of neoplasia
|
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
CN108472314A
(zh)
*
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
修饰的细胞和治疗方法
|
|
JP2018522907A
(ja)
*
|
2015-08-11 |
2018-08-16 |
セレクティスＣｅｌｌｅｃｔｉｓ |
Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞
|
|
ES2929110T3
(es)
|
2015-08-25 |
2022-11-24 |
Univ Duke |
Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN
|
|
CN108135932A
(zh)
*
|
2015-08-28 |
2018-06-08 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
|
CA2998894A1
(en)
*
|
2015-09-18 |
2017-03-23 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
|
MX2018003308A
(es)
*
|
2015-09-18 |
2018-11-09 |
The General Hospital Corp Dba Massacsetts General Hospital |
Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
|
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
WO2017059241A1
(en)
|
2015-10-02 |
2017-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
|
KR20250013291A
(ko)
*
|
2015-10-05 |
2025-01-31 |
프리시젼 바이오사이언시스 인코포레이티드 |
변형된 인간 t 세포 수용체 알파 불변 영역 유전자를 포함하는 유전자 변형된 세포
|
|
CA3001008A1
(en)
|
2015-10-05 |
2017-04-13 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
|
CA3001130A1
(en)
*
|
2015-10-16 |
2017-04-20 |
Temple University - Of The Commonwealth System Of Higher Education |
Methods and compositions utilizing cpf1 for rna-guided gene editing
|
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
|
WO2017070429A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
CA3002827A1
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
EA201891092A1
(ru)
*
|
2015-11-04 |
2018-10-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Способы и композиции для редактирования генов в гемопоэтических стволовых клетках
|
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
CA3007115A1
(en)
|
2015-12-04 |
2017-06-08 |
Memorial Sloan-Kettering Cancer Center |
Antibodies targeting fc receptor-like 5 and methods of use
|
|
SG11201804373VA
(en)
*
|
2015-12-04 |
2018-06-28 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
|
CN106967681B
(zh)
*
|
2016-01-13 |
2020-06-05 |
北京马力喏生物科技有限公司 |
治疗脑胶质母细胞瘤的治疗组合物
|
|
CN106967685B
(zh)
*
|
2016-01-13 |
2020-06-02 |
北京马力喏生物科技有限公司 |
共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
|
UA125252C2
(uk)
|
2016-01-21 |
2022-02-09 |
Пфайзер Інк. |
Химерний антигенний рецептор, що націлений на варіант iii рецептора епідермального фактора росту
|
|
IL291971B2
(en)
*
|
2016-03-04 |
2025-04-01 |
Editas Medicine Inc |
CRISPR–CPF1 related methods, compositions and components for cancer immunotherapy
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
US20190161530A1
(en)
*
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
WO2017177149A2
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
EP3429633B1
(en)
*
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
ES2933961T3
(es)
|
2016-04-15 |
2023-02-15 |
Memorial Sloan Kettering Cancer Center |
Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados
|
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
|
CN107304434A
(zh)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
一种免疫细胞治疗的双功能新型载体
|
|
WO2017193107A2
(en)
*
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
LT3474669T
(lt)
|
2016-06-24 |
2022-06-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Barkodu pažymėtų kombinatorinių bibliotekų generavimo būdai
|
|
JP7195154B2
(ja)
*
|
2016-07-06 |
2022-12-23 |
セレクティス |
初代免疫細胞における逐次遺伝子編集
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2017306557B2
(en)
|
2016-08-03 |
2023-08-03 |
Washington University |
Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
KR102827276B1
(ko)
|
2016-08-03 |
2025-07-01 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
JP7201153B2
(ja)
|
2016-08-09 |
2023-01-10 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
|
|
WO2018031762A1
(en)
*
|
2016-08-10 |
2018-02-15 |
Duke University |
Compositions, systems and methods for programming immune cell function through targeted gene regulation
|
|
SG11201901184QA
(en)
|
2016-08-12 |
2019-03-28 |
Toolgen Inc |
Manipulated immunoregulatory element and immunity altered thereby
|
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
KR20190046854A
(ko)
|
2016-09-14 |
2019-05-07 |
얀센 바이오테크 인코포레이티드 |
Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
|
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
WO2018075664A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
EP3529265A2
(en)
*
|
2016-10-19 |
2019-08-28 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
US11873511B2
(en)
|
2016-10-19 |
2024-01-16 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
EP4644554A2
(en)
|
2016-10-31 |
2025-11-05 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
|
|
US20190263906A1
(en)
|
2016-11-10 |
2019-08-29 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
|
|
EP3321280B8
(en)
|
2016-11-10 |
2021-03-10 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
|
|
US12227578B2
(en)
|
2016-11-11 |
2025-02-18 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
|
|
WO2018098365A2
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR20190085528A
(ko)
|
2016-11-22 |
2019-07-18 |
싱가포르국립대학교 |
T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단
|
|
AU2017363970A1
(en)
|
2016-11-23 |
2019-06-20 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
|
EP3559214A1
(en)
*
|
2016-12-21 |
2019-10-30 |
UCL Business PLC |
Therapeutic cells
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
CN107760680B
(zh)
*
|
2016-12-28 |
2020-09-22 |
北京微旋基因技术有限公司 |
特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
|
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
CN110520156A
(zh)
*
|
2017-01-29 |
2019-11-29 |
唐泽群 |
针对外源抗原和/或自身抗原的免疫调控方法
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
WO2018148224A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
|
AU2018222749B2
(en)
|
2017-02-17 |
2024-04-18 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
EP3589291A4
(en)
|
2017-02-28 |
2020-11-25 |
Vor Biopharma, Inc. |
COMPOSITIONS AND METHODS OF INHIBITION OF LINE-SPECIFIC PROTEINS
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
RU2019133280A
(ru)
|
2017-03-22 |
2021-04-22 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
BR112019019655A2
(pt)
|
2017-03-23 |
2020-04-22 |
Harvard College |
editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
|
|
AU2018246377B2
(en)
|
2017-03-31 |
2025-01-30 |
Cellectis Sa |
Universal anti-CD22 chimeric antigen receptor engineered immune cells
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
CN111093691A
(zh)
|
2017-04-03 |
2020-05-01 |
内恩疗法公司 |
蛋白质抗原及其用途
|
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
|
|
EP3391907B8
(en)
|
2017-04-20 |
2020-03-04 |
iOmx Therapeutics AG |
Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
|
|
AU2018264636B2
(en)
|
2017-05-08 |
2022-03-17 |
Toolgen Incorporated |
Artificially manipulated immune cell
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
CN110770348B
(zh)
*
|
2017-06-01 |
2023-12-15 |
浙江煦顼技术有限公司 |
嵌合抗原受体细胞的制备及其用途
|
|
PE20241587A1
(es)
|
2017-06-02 |
2024-08-01 |
Pfizer |
Receptores de antigenos quimericos que se dirigen a flt3
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
BR112019026625A2
(pt)
|
2017-06-15 |
2020-06-30 |
The Regents Of The University Of California |
inserções de dna não viral direcionadas
|
|
WO2018237300A1
(en)
*
|
2017-06-22 |
2018-12-27 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US12144825B2
(en)
|
2017-06-30 |
2024-11-19 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
EP3645038A1
(en)
|
2017-06-30 |
2020-05-06 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
AU2018304173A1
(en)
|
2017-07-17 |
2020-01-30 |
Janssen Biotech, Inc. |
Antigen binding regions against fibronectin type III domains and methods of using the same
|
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019050948A1
(en)
|
2017-09-05 |
2019-03-14 |
Regeneron Pharmaceuticals, Inc. |
ADMINISTRATION OF A GENE EDITION SYSTEM HAVING ONLY ONE RETROVIRAL PARTICLE AND METHODS OF GENERATING AND USING
|
|
TW201920661A
(zh)
*
|
2017-09-18 |
2019-06-01 |
大陸商博雅輯因（北京）生物科技有限公司 |
一種基因編輯t細胞及其用途
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
KR102338449B1
(ko)
|
2017-09-21 |
2021-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
MX2020003536A
(es)
|
2017-10-03 |
2020-09-14 |
Juno Therapeutics Inc |
Moleculas de union especifica a virus de papiloma humano (hpv).
|
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
|
IL273828B2
(en)
*
|
2017-10-19 |
2024-06-01 |
Cellectis Sa |
Targeted gene integration of nk inhibitors genes for improved immune cells therapy
|
|
JP2021501156A
(ja)
*
|
2017-10-27 |
2021-01-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定
|
|
WO2019084552A1
(en)
|
2017-10-27 |
2019-05-02 |
The Regents Of The University Of California |
TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS
|
|
CN111511370A
(zh)
|
2017-11-01 |
2020-08-07 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
|
|
EP3703750B1
(en)
|
2017-11-01 |
2024-12-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
|
|
JP7261232B2
(ja)
|
2017-11-01 |
2023-04-19 |
アロジーン セラピューティクス，インコーポレイテッド |
改変カスパーゼ－９ポリペプチドおよびその使用方法
|
|
CN109750035B
(zh)
*
|
2017-11-02 |
2020-06-05 |
上海邦耀生物科技有限公司 |
靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
|
|
MA50564A
(fr)
|
2017-11-06 |
2020-09-16 |
Hutchinson Fred Cancer Res |
Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
|
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
US11738047B2
(en)
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
|
CA3088234A1
(en)
|
2018-01-12 |
2019-07-18 |
Curocell Inc. |
Enhanced immune cells using dual shrna and composition including the same
|
|
WO2019144091A1
(en)
|
2018-01-22 |
2019-07-25 |
Endocyte, Inc. |
Methods of use for car t cells
|
|
PT110526B
(pt)
|
2018-01-26 |
2021-02-04 |
Univ Nova De Lisboa |
Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
|
|
EP3746483A1
(en)
|
2018-02-01 |
2020-12-09 |
Pfizer Inc |
Chimeric antigen receptors targeting cd70
|
|
CN111936519A
(zh)
|
2018-02-01 |
2020-11-13 |
辉瑞公司 |
对cd70具有特异性的抗体及其用途
|
|
WO2019156795A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
US20200224160A1
(en)
*
|
2018-02-27 |
2020-07-16 |
Sorrento Therapeutics, Inc. |
Process for dna integration using rna-guided endonucleases
|
|
WO2019166946A1
(en)
|
2018-02-28 |
2019-09-06 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
|
CN112292139B
(zh)
*
|
2018-03-13 |
2024-03-08 |
明尼苏达大学董事会 |
使用Cas9碱基编辑器的淋巴造血改造
|
|
EP3775229A4
(en)
|
2018-03-27 |
2021-12-15 |
The Trustees Of The University Of Pennsylvania |
MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTION AND SCREENING METHODS TO IDENTIFY THEM
|
|
EP3775237A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2019195492A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
EP4275697A3
(en)
|
2018-04-12 |
2024-01-17 |
Precision BioSciences, Inc. |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
SG11202007878UA
(en)
|
2018-04-27 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Expression of foxp3 in edited cd34+ cells
|
|
CA3099401A1
(en)
*
|
2018-05-07 |
2019-11-14 |
The Regents Of The University Of California |
Compositions and methods for modifying regulatory t cells
|
|
WO2019215500A1
(en)
|
2018-05-11 |
2019-11-14 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
JP2021523745A
(ja)
|
2018-05-16 |
2021-09-09 |
シンテゴ コーポレイション |
ガイドｒｎａ設計および使用のための方法およびシステム
|
|
KR20210010555A
(ko)
*
|
2018-05-17 |
2021-01-27 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
약물 저항성 면역 세포 및 그의 사용 방법
|
|
SG11202010996QA
(en)
|
2018-05-23 |
2020-12-30 |
Nat Univ Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2019237398A1
(zh)
*
|
2018-06-16 |
2019-12-19 |
深圳市博奥康生物科技有限公司 |
一种特异靶向人CD272基因的gRNA导向序列及其应用
|
|
US12246067B2
(en)
|
2018-06-19 |
2025-03-11 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
|
US12391685B2
(en)
|
2018-08-20 |
2025-08-19 |
The Broad Institute, Inc. |
Inhibitors of RNA-guided nuclease target binding and uses thereof
|
|
US12460244B2
(en)
|
2018-08-20 |
2025-11-04 |
The Broad Institute, Inc. |
Inhibitors of RNA-guided nuclease activity and uses thereof
|
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
|
JP2022520138A
(ja)
|
2018-08-28 |
2022-03-29 |
ブイオーアール バイオファーマ インコーポレーテッド |
遺伝子操作された造血幹細胞およびそれらの使用
|
|
SG11202101773WA
(en)
|
2018-08-29 |
2021-03-30 |
Nanjing Legend Biotech Co Ltd |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
US11845958B2
(en)
*
|
2018-09-05 |
2023-12-19 |
Wisconsin Alumni Research Foundation |
Genetically modified genes and cells, and methods of using same for silencing virus gene expression
|
|
AU2019341365A1
(en)
*
|
2018-09-21 |
2021-05-27 |
Crage Medical Co., Limited |
Method for gene editing of cell on the basis of CRISPR/Cas system
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020072250A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
|
|
US12203123B2
(en)
|
2018-10-01 |
2025-01-21 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
|
|
WO2020072254A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for killing target cells
|
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081613A1
(en)
*
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
WO2020081922A1
(en)
|
2018-10-18 |
2020-04-23 |
University Of Utah Research Foundation |
Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
EP3887507A1
(en)
|
2018-11-30 |
2021-10-06 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109722437B
(zh)
*
|
2018-12-29 |
2020-01-07 |
广州百暨基因科技有限公司 |
一种通用型car-t细胞及其制备方法和用途
|
|
CN109652378B
(zh)
*
|
2018-12-29 |
2020-04-24 |
广州百暨基因科技有限公司 |
一种功能增强的通用型car-t细胞及其制备方法和用途
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
GB2601617B
(en)
|
2019-03-19 |
2024-02-21 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
|
AU2020248370A1
(en)
*
|
2019-03-22 |
2021-11-11 |
Spotlight Therapeutics |
Targeted active gene editing agent and methods of use
|
|
EP3956349A1
(en)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
WO2020222176A1
(en)
|
2019-04-30 |
2020-11-05 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
|
EP3736330A1
(en)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Modified adeno-associated virus (aav) particles for gene therapy
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
CA3146023A1
(en)
|
2019-07-05 |
2021-01-14 |
Iomx Therapeutics Ag |
Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
AU2020337428A1
(en)
|
2019-08-27 |
2022-03-17 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
|
WO2021146641A1
(en)
|
2020-01-17 |
2021-07-22 |
The Broad Institute, Inc. |
Small type ii-d cas proteins and methods of use thereof
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
AU2021232141A1
(en)
|
2020-03-03 |
2022-09-22 |
Janssen Biotech, Inc. |
ꝩδ T cells and uses thereof
|
|
BR112022017924A2
(pt)
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
|
WO2021188384A1
(en)
*
|
2020-03-14 |
2021-09-23 |
Berkeley Lights, Inc. |
Methods of amplifying paired transcript sequences from single cells
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
EP4146804A1
(en)
|
2020-05-08 |
2023-03-15 |
The Broad Institute Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
EP3910331A1
(en)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
|
|
WO2021257716A2
(en)
|
2020-06-16 |
2021-12-23 |
Bio-Techne Corporation |
Engineered mad7 directed endonuclease
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
EP4175668A1
(en)
|
2020-07-06 |
2023-05-10 |
iOmx Therapeutics AG |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
|
KR20230040331A
(ko)
|
2020-07-21 |
2023-03-22 |
알로젠 테라퓨틱스 인코포레이티드 |
강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도
|
|
EP3957720A1
(en)
|
2020-08-21 |
2022-02-23 |
Charité - Universitätsmedizin Berlin |
Immunosuppressant-resistant t-cells for adoptive immunotherapy
|
|
EP4196572A1
(en)
*
|
2020-08-14 |
2023-06-21 |
Charité - Universitätsmedizin Berlin |
Immunosuppressant-resistant t-cells for adoptive immunotherapy
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
WO2022101363A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
US20240175013A1
(en)
*
|
2020-12-14 |
2024-05-30 |
Emendobio Inc. |
Biallelic knockout of trac
|
|
EP4039808A1
(en)
*
|
2021-02-08 |
2022-08-10 |
Ospedale San Raffaele S.r.l. |
Guide rnas and uses thereof
|
|
EP4301755A1
(en)
|
2021-03-03 |
2024-01-10 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
WO2022215978A1
(ko)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
CA3247927A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics Inc |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
JP2025506976A
(ja)
*
|
2022-03-04 |
2025-03-13 |
ツールゲン インコーポレイテッド |
低免疫原性幹細胞、幹細胞から分化または由来した低免疫原性細胞およびこの製造方法
|
|
WO2023179766A1
(zh)
|
2022-03-24 |
2023-09-28 |
南京传奇生物科技有限公司 |
制备dna文库和检测逆转录病毒整合位点的方法
|
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
AU2023289696A1
(en)
|
2022-06-24 |
2025-01-16 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
TW202426641A
(zh)
|
2022-08-19 |
2024-07-01 |
美商圖恩療法股份有限公司 |
以靶向基因抑制來調節b型肝炎病毒之組合物、系統和方法
|
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
JP2025531268A
(ja)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Ｔ細胞機能を調節するための組成物、システム、および方法
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN120936625A
(zh)
|
2023-01-12 |
2025-11-11 |
新加坡国立大学 |
用于t细胞和nk细胞恶性肿瘤的免疫疗法的cd8表达阻断和嵌合抗原受体
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
TW202519537A
(zh)
|
2023-07-21 |
2025-05-16 |
義大利商博雷亞醫療有限責任公司 |
經化學遺傳表面修飾之病毒顆粒
|
|
WO2025021771A1
(en)
|
2023-07-21 |
2025-01-30 |
Borea Therapeutics S.R.L. |
Methods of preparing surface modified viral capsids
|
|
LU504827B1
(en)
|
2023-07-28 |
2025-01-28 |
Univ Saarland |
Compounds and compositions for use in the treatment of lung diseases
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025096907A1
(en)
*
|
2023-11-01 |
2025-05-08 |
The Children's Medical Center Corporation |
Methods and compositions for immunosuppressant resistant cellular therapies
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025196087A1
(en)
|
2024-03-19 |
2025-09-25 |
Borea Therapeutics S.R.L. |
Targeting tissues in the cns
|
|
WO2025212519A1
(en)
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|